The HIV clinical trials market involves various stages of clinical research being conducted to develop new treatment strategies and drugs for HIV/AIDS. The market consists of antiretroviral drugs, vaccines, pre-exposure prophylaxis, microbicides, and other emerging therapeutics being tested for the treatment and prevention of HIV infection. Significant research investments and collaborations between drug manufacturers, academic institutions, and non-profit organizations are being made to advance the clinical development of novel HIV therapies.
Global HIV clinical trials market is estimated to be valued at USD 1.48 Bn in 2024 and is expected to reach USD 2.19 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.
Key Takeaways
Key players operating in the HIV clinical trials market are Gilead Sciences, Inc., Johnson Johnson, Merck Co. These leading pharmaceutical companies are investing heavily in developing new classes of antiretroviral drugs with improved efficacy and safety profiles. For instance, Gilead Sciences' Biktarvy and Merck's Doravirine are some of the best-selling brands in the market.
The growing burden of HIV/AIDS globally is driving increased HIV Clinical Trials Market Growth for new treatment options. According to UNAIDS, around 38 million people were living with HIV/AIDS worldwide in 2020, underscoring the need for continual research on newer drugs and prevention methods.
Technological advancements such as therapies targeting viral reservoirs and gene therapy holds promise for a potential cure. Biotechs are exploring several novel mechanisms of action beyond traditional antiretroviral drugs to achieve long-term remission without lifelong treatment.
Market Trends
Growing Research on Long-Acting Injectables: Long-acting injectable antiretrovirals administered every 2-3 months can improve treatment adherence compared to daily oral pills. Drugs under evaluation include Cabotegravir, Lenacapavir, and Islatravir.
Increased Focus on Developing Integrated Therapies: Combination therapies integrating antiretrovirals with other agents such as cancer drugs, anti-inflammatory, and gene therapies hold potential to achieve functional cures.
Get More Insights On- HIV Clinical Trials Market
